NASDAQ:MGTX - MeiraGTx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.70 +0.13 (+1.23 %)
(As of 07/18/2018 12:37 PM ET)
Previous Close$10.64
Today's Range$10.64 - $10.70
52-Week Range$10.27 - $15.49
Volume500 shs
Average Volume85,980 shs
Market Capitalization$291.96 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGTX
CUSIPN/A
Phone646-490-2965

Debt

Debt-to-Equity RatioN/A
Current Ratio2.59
Quick Ratio2.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees59
Outstanding Shares27,180,000
Market Cap$291.96

The Truth About Cryptocurrencies

MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

What price target have analysts set for MGTX?

3 brokers have issued 12 month price targets for MeiraGTx's shares. Their predictions range from $20.00 to $21.00. On average, they expect MeiraGTx's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 91.6% from the stock's current price. View Analyst Ratings for MeiraGTx.

What is the consensus analysts' recommendation for MeiraGTx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of MeiraGTx's key competitors?

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the folowing people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 53)
  • Mr. Richard Brian Giroux, Chief Operating Officer (Age 45)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 55)
  • Prof. Gregory A. Petsko, Chief Scientist & Chairman of Scientific Advisory Board
  • Prof. Robin Ali, Head of Preclinical Ophthalmology & Member of Scientific Advisory Board

When did MeiraGTx IPO?

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

When did MeiraGTx's quiet period expire?

MeiraGTx's quiet period expired on Wednesday, July 18th. MeiraGTx had issued 5,000,000 shares in its public offering on June 8th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. During MeiraGTx's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Has MeiraGTx been receiving favorable news coverage?

Media coverage about MGTX stock has been trending somewhat positive on Wednesday, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MeiraGTx earned a news impact score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 44.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $10.70.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $291.96 million. MeiraGTx employs 59 workers across the globe.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]


MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  18
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: Short Selling

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.